Protocols
Research Stage
PT-141 (bremelanotide) carries a formal FDA contraindication in patients with known cardiovascular disease or uncontrolled hypertension. In controlled trials, the 1.75 mg subcutaneous dose transiently raised mean systolic blood pressure by approximately 3 mmHg and lowered heart rate by roughly 2 bpm — effects that resolve within 12 hours but pose disproportionate risk in patients with compromised cardiac reserve.